REMARKS/ARGUEMENTS

Claim 1 is further amended by restricting N and variables R3, R4 to a specific pyrrolidinyl heterocycle, and deleting alkyl of C1-C6 from variable R5. Accordingly, claim 1 is no longer anticipated by the cited references, Kang et al. publication and Carreno et al. publication.

Applicant developed a series of amino compounds, though exemplified by only one preferred embodiment, and proved their superior effect of catalization. As shown in this application, only an amount of 1/2,000~5,000 of the elected species based on the substrate is required to achieve 98% or more enantiomeric excess (e.e.). Such performance has not been indicated in any prior reference. The key issue to be a good catalyst of a reaction is the catalyst/substrate ratio, which is the unique advantage of our claimed species and it has never been reported in the claimed system before. In Kang et al. publication, an amount as high as 1/20 based on the substrate was applied. This invention thus provides an amino compound to effectively reduce cost in application thereof.

Applicant respectfully requests that a timely Notice of Allowance be issued in this case.

Respectfully submitted,



Charles E. Baxley

90 John Street-Third Floor
New York, N.Y. 10038-3243
U.S.A.
TEL: (212) 791-7200
FAX: (212) 791-7276